Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526448 | 0.98 | TRPV1 (0.42) | TRPV1CYP1A2LMNAMEN1KMT2A | |
| SCHEMBL2526439 | 0.98 | TRPV1 (0.42) | TRPV1CYP1A2LMNAMEN1KMT2A | |
| SCHEMBL2162686 | 0.85 | TRPV1 (0.51) | TRPV1TSHR | |
| SCHEMBL2555362 | 0.84 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL2553309 | 0.83 | TRPV1 (0.47) | TRPV1 | |
| SCHEMBL2523041 | 0.81 | TRPV1 (0.43) | TRPV1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL2529549 | 0.81 | TRPV1 (0.43) | TRPV1LMNAMAPK1SMN1; SMN2 | |
| SCHEMBL2526590 | 0.80 | DHFR (0.41) | TRPV1 | |
| SCHEMBL15831847 | 0.79 | CYP1A2 (0.41) | TRPV1CYP1A2LMNAMEN1KMT2A | |
| SCHEMBL2553893 | 0.78 | HPGD (0.42) | TRPV1CYP1A2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | GRUENENTHAL GMBH (DE) | 2014-06-26 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710233-B2 | Vanilloid receptor ligands and use thereof for the production of pharmaceutical preparations | GRUENENTHAL GMBH (DE) | 2014-04-29 | — | — | US | disclosed |
| EP-1940821-B1 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-1940821-B1 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2388258-A1 | Novel vanilloid receptor ligands and their use for producing medicaments | Grünenthal GmbH (DE) | 2011-11-23 | — | — | EP | disclosed |
| EP-2388258-A1 | Novel vanilloid receptor ligands and their use for producing medicaments | Grünenthal GmbH (DE) | 2011-11-23 | — | — | EP | disclosed |
| US-8038010-B1 | Single piece edge protector for curved objects | ILLINOIS TOOL WORKS INC. (US) | 2011-10-18 | — | — | US | disclosed |
| EP-1940821-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | GRUENENTHAL GMBH (DE) | 2007-05-10 | — | — | US | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045462-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THEIR USE FOR PRODUCING MEDICAMENTS | Grünenthal GmbH (DE) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105861-A1 | NOVEL VANILLOID RECEPTOR LIGANDS AND USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885CYP1A2 1857/4885LMNA 3586/4885 |
| US-20140179686-A1 | Novel Vanilloid Receptor Ligands and Use Thereof for the Production of Pharmaceutical Preparations | TRPV1, TRPV5, TRPV2 | TRPV1 1/4885CYP1A2 1857/4885LMNA 3586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.